Related Experiment Videos
Toxicity of high-dose flurazepam in the elderly
Abstract:
To assess the potential hazards of flurazepam (Dalmane) therapy of insomnia in the elderly, the relation of dosage and patient age to the frequency of flurazepam-attributed adverse reactions was studied in 2,542 hospitalized medical patients. Adverse reactions, predominantly unwanted residual drowsiness, were reported in 78 flurazepam recipients (3.1%). None of the adverse reactions were serious. The frequency of reported toxicity increased with average daily dose, ranging from 1.3% among those receiving less than 15 mg/day to 12.3% at doses of 30 mg/day or more (p less than 0.001). Toxicity increased with age, progressively from 1.9% among those under 60 to 7.1% among those 80 or over (p less than 0.001). Unwanted effects of high-dose flurazepam were observed much more commonly in the elderly. Only 2.0% of those 70 years of age or older experienced adverse reactions at doses under 15 mg/day, as opposed to 39.0% at 30 mg or more per day. Low doses of flurazepam appear to be safe for elderly individuals, but they are susceptible to unwanted central nervous system depression at high doses.
Insights
Flurazepam (Dalmane) for insomnia can cause side effects, mainly drowsiness, especially in older adults. Higher doses increase risks, but low doses appear safe for the elderly.
Area of Science:
- Geriatric Pharmacology
- Clinical Pharmacy
- Sleep Medicine
Background:
- Insomnia is common in the elderly.
- Flurazepam is a commonly prescribed hypnotic medication.
- Potential adverse effects of flurazepam in older adults require careful evaluation.
Purpose of the Study:
- To evaluate the safety of flurazepam in elderly patients.
- To determine the relationship between flurazepam dosage, patient age, and adverse reactions.
- To assess the risk of flurazepam-attributed toxicity in hospitalized elderly patients.
Main Methods:
- Retrospective study of 2,542 hospitalized medical patients.
- Analysis of flurazepam dosage and patient age.
- Assessment of flurazepam-attributed adverse reactions, primarily residual drowsiness.
Main Results:
- Adverse reactions occurred in 3.1% of flurazepam recipients.
- Toxicity increased significantly with higher daily doses (p < 0.001).
- Toxicity increased with age, with higher rates in patients 80 years and older (p < 0.001).
- Elderly patients (≥70 years) showed a marked increase in adverse reactions at higher doses (39.0% at ≥30 mg/day vs. 2.0% at <15 mg/day).
Conclusions:
- Flurazepam dosage and patient age are critical factors in adverse reaction frequency.
- High-dose flurazepam is associated with significantly increased toxicity in the elderly.
- Low doses of flurazepam (<15 mg/day) appear safe for elderly individuals, minimizing central nervous system depression risks.